Influenza is often considered a mild illness that can resolve on its own. However, in some individuals, influenza can lead to serious complications such as pneumonia, respiratory failure, worsening of chronic diseases, and even death. The risk of complications is higher among vulnerable groups, including older adults, children, pregnant women, and individuals with chronic conditions such as diabetes, heart disease, or lung disorders.
Therefore, influenza vaccination remains one of the most effective measures to prevent infection and reduce the risk of complications caused by this disease.
For many years, seasonal influenza vaccines have been available in two types: trivalent and quadrivalent vaccines.
Quadrivalent vaccines contain four influenza virus components, namely two influenza A strains (H1N1 and H3N2) and two influenza B lineages (Victoria and Yamagata). Meanwhile, trivalent vaccines contain three components: two influenza A strains and one influenza B strain from the Victoria lineage.
In recent years, global health organizations and regulatory authorities have recommended a transition back to trivalent vaccines. This decision was made because the influenza B Yamagata lineage virus has not been detected circulating naturally since March 2020, based on global surveillance conducted through the World Health Organization (WHO) Global Influenza Surveillance and Response System (GISRS). (CDC)
To date, there is no convincing evidence that influenza B/Yamagata has resumed widespread circulation in the community. Therefore, WHO considers the Yamagata component no longer necessary in seasonal influenza vaccine formulations. (World Health Organization)
The removal of one component from the vaccine does not mean its protection is reduced. On the contrary, this change represents a scientific adjustment based on the current circulation patterns of influenza viruses.
The current trivalent influenza vaccine is formulated to protect against the three influenza virus groups that remain most relevant and actively circulating:
WHO routinely reviews global influenza surveillance data and updates vaccine composition recommendations each year to match the viruses expected to circulate during the upcoming influenza season. (World Health Organization)
Various studies have shown that trivalent vaccines continue to generate a strong immune response against relevant virus strains. In addition, their safety profile remains excellent and comparable to that of the previously used quadrivalent vaccines.
Influenza vaccines have been used for decades and have an excellent safety record. The most common side effects are generally mild and temporary, such as:
These symptoms usually improve within 1–3 days without requiring special treatment.
After vaccination, the body requires approximately two weeks to develop optimal protection. Because influenza viruses continue to change from year to year, annual vaccination is recommended according to healthcare professional guidance.
Influenza vaccination is recommended for everyone aged 6 months and older, especially those at high risk of influenza-related complications. (CDC)
Consult your doctor before vaccination, especially if you have certain medical conditions or belong to a high-risk group. With annual vaccination, the risk of contracting influenza and developing serious complications can be significantly reduced.
National Hospital provides influenza vaccination services administered by healthcare professionals in accordance with safety and quality standards. In addition, National Hospital’s Medical Check-Up services are supported by experienced medical teams and comprehensive diagnostic facilities to help maintain the health of you and your family optimally.
info@national-hospital.com
628131000517
Suggestion
Login
